Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV)

198 filings reported holding VERV - Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2024.
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) has 161 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 76,097,271 shares of 89,600,000 outstanding shares and own 85% of the company stock.
Largest 10 shareholders include Alphabet Inc. (12,349,086 shares), BlackRock Inc. (6,620,004 shares), VANGUARD GROUP INC (5,263,509 shares), T. Rowe Price Investment Management, Inc. (4,528,712 shares), MILLENNIUM MANAGEMENT LLC (3,870,840 shares), STATE STREET CORP (3,349,408 shares), Casdin Capital, LLC (3,059,094 shares), ARK Investment Management LLC (2,936,063 shares), Novo Holdings A/S (2,400,000 shares), and ARCH Venture Management, LLC (2,008,809 shares).
This table shows the top 161 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.